Authorized purpose: Voluson SWIFT and Voluson SWIFT+ are general-purpose diagnostic ultrasound systems for qualified and trained healthcare professionals to image, measure, display, and analyze the human body and fluid across the labeled fetal/obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, transrectal, and transvaginal applications in a hospital or medical clinic.
Clinical role
Diagnostic ultrasound imaging, fluid analysis, measurement, display, and analysis using the exact labeled probes and modes.
Keep in mind: Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Voluson SWIFT and Voluson SWIFT+ are general-purpose diagnostic ultrasound systems for qualified and trained healthcare professionals to image, measure, display, and analyze the human body and fluid across the labeled fetal/obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, transrectal, and transvaginal applications in a hospital or medical clinic.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal/obstetric, abdominal, renal, gynecologic/pelvic, pediatric, breast, testes, thyroid, cephalic, cardiac, vascular, musculoskeletal, transrectal, urologic, and transvaginal anatomy Input: Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.
Who uses it?Intended users: Appropriately trained healthcare professionals qualified for direct use of diagnostic ultrasound equipment.
What does the software produce?Output: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
What is its most important limitation?Key limitation: Use only the exact labeled probes, applications, modes, patient populations, and care settings; output requires qualified-professional review.
Clinical takeaway. Clinical role: Voluson SWIFT and Voluson SWIFT+ are general-purpose diagnostic ultrasound systems for qualified and trained healthcare professionals to image, measure, display, and analyze the human body and fluid across the labeled fetal/obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, transrectal, and transvaginal applications in a hospital or medical clinic.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA decision material for K230346 supports the submission-specific intended use and regulatory verification summarized here; it does not establish a general product-wide sensitivity or specificity value.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Voluson SWIFT and Voluson SWIFT+ are general-purpose diagnostic ultrasound systems for qualified and trained healthcare professionals to image, measure, display, and analyze the human body and fluid across the labeled fetal/obstetric, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, transrectal, and transvaginal applications in a hospital or medical clinic.
The exact FDA decision material for K230346 supports the submission-specific intended use and regulatory verification summarized here; it does not establish a general product-wide sensitivity or specificity value.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA decision material for K230346 supports the submission-specific intended use and regulatory verification summarized here; it does not establish a general product-wide sensitivity or specificity value.
No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K230346
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K230346; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K230346; a broader clinical population is not established here.
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound acquisitions and fluid information from supported probes, applications, patient populations, and operating modes.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes the Voluson SWIFT and SWIFT+ mobile consoles as having comprehensive networking and DICOM capability, with optional image storage and printing devices, and lists the NEMA PS 3.1-3.20 DICOM standard among the voluntary standards they comply with. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Voluson SWIFT, Voluson SWIFT+ consist of a mobile console with control panel, full touch monitor, optional image storage and printing devices. It provides high-performance ultrasound imaging and analysis and have comprehensive networking and DICOM capability." … "The Voluson SWIFT, Voluson SWIFT+ complies with voluntary standards:". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Ultrasound images, measurements, Doppler or other mode-specific information, and fluid-analysis results for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the Voluson SWIFT and SWIFT+ mobile consoles as having comprehensive networking and DICOM capability, with optional image storage and printing devices, and lists the NEMA PS 3.1-3.20 DICOM standard among the voluntary standards they comply with. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Voluson SWIFT, Voluson SWIFT+ consist of a mobile console with control panel, full touch monitor, optional image storage and printing devices. It provides high-performance ultrasound imaging and analysis and have comprehensive networking and DICOM capability." … "The Voluson SWIFT, Voluson SWIFT+ complies with voluntary standards:". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems, Ultrasound & Primary Care Diagnostics LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.
Current vendor material is product-family context for K230346 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact deployment topology, hosting, network boundaries, PHI flow, retention, update mechanism, and local operational requirements are not established for this submission.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
GE Medical Systems Ultrasound and Primary care Diagnostics
Authorized purpose: LOGIQ Totus is a general-purpose diagnostic ultrasound system for trained healthcare professionals to image, measure, display, and analyze the human body and fluid across the labeled fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, urologic, transrectal, and transvaginal applications.
Modality
Ultrasound
Anatomy
Fetal/obstetric, abdominal, renal, gynecologic/pelvic, pediatric, breast, testes, thyroid, neonatal and adult cephalic, cardiac, vascular, musculoskeletal, urologic, transrectal, and transvaginal anatomy
GE Medical Systems Ultrasound and Primary Care Diagnostic
Authorized purpose: LOGIQ E10s and LOGIQ Fortis are general-purpose diagnostic ultrasound systems for trained healthcare professionals to image, measure, display, and analyze the human body and fluid across the labeled fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, and intraoperative applications in hospitals or medical clinics.
TOMTEC-ARENA quantifies and reports cardiovascular, fetal, and abdominal structures and functions from supported clinical images and can exchange data with IMAGE-ARENA and third-party applications.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.